Skip to content
StockMarketAgent
Direct answer
PEP trades against a final fair-value range of $142.66-$206.45, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $143, high $206, with mid-point at $174.
Stock analysis

PEP PepsiCo Inc. fair value $174–$206

PEP
By StockMarketAgent.AI team· supervised by
Analisado: 2026-05-08Próxima atualização: 2026-08-08Methodology v2.4Archetype: Mature dividendNASDAQ · Consumer Staples
View archive
Preço
$154.62
▲ +19.79 (+12.80%)
Valor justo
$174
$174–$206
Classificação
Comprar
confidence 88/100
Potencial de alta
+12.8%
upside to fair value
Margem de segurança
$148.25
buy below · 15%
Capitalização de mercado
$211.4B
P/E fwd 16.9
Fonte em inglêsPT
Exibindo a fonte em inglês enquanto traduzimos
Este relatório ainda não foi traduzido. Atualize em alguns minutos assim que a fila de tradução recuperar o atraso.

§1 Resumo executivo

  • Composite fair value $174 with high case $206.
  • Implied upside of 12.8% to fair value.
  • Moat 9/10 · confidence 88/100 · Mature dividend.
  • Trades at a measured discount to fair value with adequate margin of safety.
Fair value
$174
Margin of safety
+11.3%
Confidence
88/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$154.62Price
FV $174.41
High $206.45

PEP trades against a final fair-value range of $142.66-$206.45, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Deep global distribution networks covering
    Deep global distribution networks covering developed and emerging markets.
  • Immense brand equity and pricing
    Immense brand equity and pricing power across both beverage and snack portfolios.
  • Bull thesis
    Valuation synthesis intentionally anchors heavily on Forward Earnings to mitigate terminal value dominance.

§2 Cenário pessimista

A sustained macroeconomic downturn coupled with accelerated adoption of GLP-1 weight-loss drugs leads to structural volume declines and an inability to offset cost inflation through pricing, heavily compressing operating margins and driving free cash flow below historical norms.

Como esta tese pode falhar

GLP-1 Widespread Adoption

· Medium

Mass adoption of appetite-suppressing GLP-1 drugs permanently reduces per-capita consumption of high-calorie snacks and sugary beverages, breaking historical volume baselines.

FV impact
-25%
Trigger
3-5 years

Total Loss of Pricing Power

· Low

Consumer fatigue over successive price hikes forces aggressive discounting and promotional activity to defend market share against private label brands, destroying gross margins.

FV impact
-20%
Trigger
1-2 years

Supply Chain and Input Cost Shock

· Medium

Extreme agricultural commodity inflation and localized supply chain disruptions structurally elevate the cost base beyond what can be passed to consumers, permanently compressing operating margins.

FV impact
-15%
Trigger
1-3 years
Sinais de alerta antecipado para monitorar
MétricaAtualLimite de gatilho
Consecutive quarters of negative organic volume growth.MonitorDeterioration versus the report thesis
Gross margin compression exceeding 150 basis points.MonitorDeterioration versus the report thesis
Substantial shift in market share to private label brands.MonitorDeterioration versus the report thesis
Significant downward revisions in forward consensus earnings.MonitorDeterioration versus the report thesis
Unplanned increases in promotional spend to clear inventory.MonitorDeterioration versus the report thesis

§3 Histórico financeiro

Demonstração de resultados — últimos seis períodos
ItemT−0T−1T−2T−3CAGR
Período2022-12-312023-12-312024-12-312025-12-31Trend
Receita$86.39B$91.47B$91.85B$93.93B+2.8%
Lucro bruto$45.82B$49.59B$50.11B$50.86B+3.5%
Lucro operacional$11.36B$12.91B$12.92B$13.49B+5.9%
Lucro líquido$8.91B$9.07B$9.58B$8.24B-2.6%
LPA (diluído)$6.42$6.56$6.95$6.00-2.2%
EBITDA$14.92B$15.75B$16.68B$15.54B+1.4%
P&D
SG&A$34.46B$36.68B$37.19B$37.37B+2.7%

Pontuações de qualidade

Piotroski F-score
5 / 9
Composto de qualidade 0–9
Altman Z-score
3.59
Risco de falência (>3 seguro)
Beneish M-score
-2.56
Risco de manipulação de lucros
OCF / Lucro líquido
1.47×
>1 indica alta qualidade dos lucros
Limite de qualidade contábil
Pass
Limite ajustado ao setor
ROIC
12.8%
Retorno sobre o capital investido
Seção 3

Numbers analysis

Alocação de capital

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Assinantes individuais — a partir do §411 seções a mais

Leia a análise completa — 11 seções a mais.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Relatório completo para cada ticker coberto
24 meses de arquivo de classificações
Briefings da lista de acompanhamento + alertas de mudança de classificação
Exportação PDF + DOCX em qualquer idioma
Iniciar teste grátis
Cancele a qualquer momento.
FAQ

PEP — frequently asked questions

  1. Based on our latest analysis, PEP looks modestly undervalued. The current price is $155 versus a composite fair-value midpoint of $174 (range $143–$206), which implies roughly 12.8% upside to the midpoint.
Related coverage

Names readers of PEP also follow

Same archetype: mature-dividend
Same sector: Consumer Staples